8-K: Eledon Tegoprubart Shows Strong Kidney Transplant Data

Eledon Pharmaceuticals announced updated Phase 1b data for tegoprubart, showing superior kidney function and graft survival predictions compared to standard of care in transplant patients.

Summary

• Eledon Pharmaceuticals presented updated data from its ongoing Phase 1b open-label trial of tegoprubart for preventing organ rejection in kidney transplant patients.
• Patients who remained on tegoprubart for a year (n=12) showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 68 mL/min/1.73 m2 post-transplant.
• The intention-to-treat population (n=15) had an eGFR of approximately 63 mL/min/1.73 m2 at 12 months.
• This compares favorably to historical studies using standard of care calcineurin inhibitor-based immunosuppression, which typically report aggregate mean eGFRs of approximately 53 mL/min/1.73 m2 during the first year.
• Preliminary iBox data, a composite biomarker panel, suggests tegoprubart may improve 5-year graft survival.
• Abbreviated iBox scores were -3.75 in the intention-to-treat population and -4.11 in the on-treatment population, compared to a -2.98 historical mean for calcineurin inhibitors.
• A difference of -0.40 in iBox score at 12 months predicts a 4-5% difference in 5-year graft survival, suggesting tegoprubart may lead to over 96% 5-year allograft survival.
• Tegoprubart continues to be well tolerated with no cases of death, graft loss, drug-related tremor, or new-onset diabetes.
• Six (18.8%) rejection episodes occurred, all successfully treated. Patients who experienced rejection but remained on tegoprubart had a mean eGFR of approximately 73 mL/min/1.73 m2 at 12 months, indicating full recovery.

Sentiment

Score: 9

Explanation: The updated Phase 1b data for tegoprubart shows significantly better kidney function and predicted graft survival compared to current standard of care, coupled with a favorable safety profile. This strong clinical performance, especially in a critical area like organ transplantation, indicates high potential for the drug and the company.

Positives

• Tegoprubart demonstrated superior kidney function (eGFR) compared to historical standard of care, with a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 versus 53 mL/min/1.73 m2 for standard of care.
• Preliminary iBox data suggests a potential improvement in 5-year graft survival, with predicted rates over 96% compared to historical calcineurin inhibitor data.
• The drug was well-tolerated, with no reported cases of death, graft loss, drug-related tremor, or new-onset diabetes, which are common side effects of standard immunosuppression.
• All six (18.8%) rejection episodes were successfully treated, and patients who remained on tegoprubart post-rejection showed full recovery of kidney function (mean eGFR of approximately 73 mL/min/1.73 m2 at 12 months).
• The data reinforces the potential for tegoprubart to offer a safer alternative to traditional immunosuppressive therapies by minimizing harmful side effects.

Negatives

• Six (18.8%) rejection episodes occurred in the study, indicating that tegoprubart alone does not completely eliminate rejection risk.
• Patients who experienced a rejection episode and switched to standard of care tacrolimus had a significantly lower mean eGFR of approximately 34 mL/min/1.73 m2 at 12 months, highlighting the importance of continued tegoprubart treatment for optimal outcomes.
• The data presented is from an open-label Phase 1b trial, which is preliminary and not a randomized controlled trial.
• The iBox data is "preliminary abbreviated iBox data," and while promising, it is not final.

Risks

• Risks relating to the safety and efficacy of drug candidates.
• Risks relating to clinical development timelines, including interactions with regulators and clinical sites, as well as patient enrollment.
• Risks relating to costs of clinical trials and the sufficiency of the company's capital resources to fund planned clinical trials.
• Actual results may differ materially from forward-looking statements due to various factors.

Future Outlook

Eledon Pharmaceuticals anticipates topline results from its Phase 2 BESTOW trial, which compares tegoprubart to tacrolimus (current standard of care), in November 2025. The company believes tegoprubart has the potential to provide better protection and long-term preservation of kidney function while offering a safer alternative to traditional immunosuppressive therapies.

Management Comments

• "The data presented today at WTC further reinforce our belief that tegoprubart has the potential to not only provide better protection and long-term preservation of kidney function following transplantation, but also to offer a safer alternative to traditional immunosuppressive therapies by minimizing harmful side effects."
• "The continued strength of the Phase 1b data through 12 months of treatment is highly encouraging as we look ahead to topline results from our Phase 2 BESTOW trial, expected in November, which compares tegoprubart to tacrolimus, the current standard of care."

Industry Context

The announcement positions tegoprubart as a promising novel immunosuppressive therapy in the kidney transplantation field, aiming to address the limitations of current standard of care treatments like calcineurin inhibitors, which are associated with significant side effects such as drug-related tremor and new-onset diabetes. The use of the iBox composite biomarker panel, which is recognized by the EMA and accepted by the U.S. FDA for its biomarker qualification program, highlights the company's alignment with advanced prognostic tools in transplant medicine, potentially accelerating regulatory pathways.

Comparison to Industry Standards

• Tegoprubart's mean 12-month eGFR of approximately 68 mL/min/1.73 m2 for patients remaining on treatment significantly outperforms the historical aggregate mean eGFR of approximately 53 mL/min/1.73 m2 reported for calcineurin inhibitor-based immunosuppression therapy during the first year after kidney transplant.
• Preliminary abbreviated iBox scores of -3.75 (ITT) and -4.11 (on-treatment) for tegoprubart compare favorably to a -2.98 historical mean for calcineurin inhibitors, suggesting a predicted 5-year allograft survival rate of over 96% for tegoprubart, which is a substantial improvement over current standards.
• Tegoprubart's safety profile, with no cases of death, graft loss, drug-related tremor, or new-onset diabetes, contrasts positively with standard of care immunosuppression therapies known for such adverse effects.
• The recovery of kidney function (mean eGFR of approximately 73 mL/min/1.73 m2 at 12 months) in patients who experienced rejection but remained on tegoprubart demonstrates a superior outcome compared to patients who switched to tacrolimus (mean eGFR of approximately 34 mL/min/1.73 m2).

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical trial results, which could increase the company's valuation and future revenue potential if the drug progresses successfully.
• Patients: Significant positive impact as tegoprubart offers the potential for better long-term kidney function, improved graft survival, and fewer severe side effects compared to existing immunosuppressive therapies.
• Medical Professionals: Provides a potentially superior treatment option for kidney transplant patients, improving patient outcomes and quality of life.
• Regulatory Authorities: The use of FDA-accepted biomarkers like iBox could streamline future regulatory approvals.

Next Steps

• Topline results from the Phase 2 BESTOW trial are anticipated in November 2025.
• Ongoing enrollment for Cohort 2 of the Phase 1b study evaluating a lower tegoprubart dose (10 mg/kg).
• Continued evaluation in the long-term safety and efficacy extension study (NCT06126380).

Key Dates

Recommendation

The updated Phase 1b data for tegoprubart is exceptionally strong, demonstrating superior efficacy in kidney function and predicted graft survival, along with a significantly better safety profile compared to the current standard of care. This positions Eledon Pharmaceuticals with a highly promising therapeutic candidate in a critical medical area. The upcoming Phase 2 results in November 2025 represent a significant near-term catalyst. Given the compelling data and market potential, the stock is a strong buy for investors seeking exposure to innovative biotechnology with de-risked clinical assets.

Keywords

Eledon Pharmaceuticals, Tegoprubart, Kidney Transplant, Organ Rejection, Immunosuppression, Phase 1b Trial, eGFR, iBox, Biotechnology, Clinical Stage, Anti-CD40L Antibody, Transplant Medicine, Drug Development